Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
115,789,112
-
Total 13F shares
-
17,671,668
-
Share change
-
+704,888
-
Total reported value
-
$439,163,056
-
Put/Call ratio
-
217%
-
Price per share
-
$24.85
-
Number of holders
-
84
-
Value change
-
+$20,668,372
-
Number of buys
-
44
-
Number of sells
-
29
Institutional Holders of Intellia Therapeutics, Inc. - Common Stock (NTLA) as of Q3 2017
As of 30 Sep 2017,
Intellia Therapeutics, Inc. - Common Stock (NTLA) was held by
84 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,671,668 shares.
The largest 10 holders included
Atlas Venture Associates IX, LLC, FMR LLC, ORBIMED ADVISORS LLC, BlackRock Inc., BAKER BROS. ADVISORS LP, VANGUARD GROUP INC, Temasek Holdings (Private) Ltd, Global Thematic Partners, LLC, Ark Investment Management LLC, and GMT CAPITAL CORP.
This page lists
84
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.